These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37819840)

  • 21. Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population.
    Rozette NA; Hellauer CM; McKee C; Vazifedan T; Gabriel CA; Dice JE; Yokois NU
    Inflamm Bowel Dis; 2018 Aug; 24(9):2007-2014. PubMed ID: 29788416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors Associated with Delays in Initiating Biologic Therapy in Patients with Inflammatory Bowel Disease.
    Abadir A; Troia A; Said H; Tarugu S; Billingsley BC; Sairam N; Minchenberg SB; Owings AH; Parker AM; Brousse B; Carlyle A; Owens BR; Hosseini-Carroll P; Galeas-Pena M; Frasca J; Glover SC; Papamichael K; Cheifetz AS
    Dig Dis Sci; 2024 Aug; 69(8):2796-2803. PubMed ID: 38963462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proactive infliximab is more effective than vedolizumab in inducing fecal calprotectin remission in inflammatory bowel disease.
    Fernandes SR; Rodrigues IC; Serrazina J; Botto IA; Bernardo S; Gonçalves AR; Valente A; Moura Santos P; Correia LA; Marinho RT
    Scand J Gastroenterol; 2022 Oct; 57(10):1202-1208. PubMed ID: 35599574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infliximab for very early-onset inflammatory bowel disease: A tertiary center experience in Japan.
    Takeuchi I; Kaburaki Y; Arai K; Shimizu H; Hirano Y; Nagata S; Shimizu T
    J Gastroenterol Hepatol; 2020 Apr; 35(4):593-600. PubMed ID: 31425641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
    Ben-Horin S; Ungar B; Kopylov U; Lahat A; Yavzori M; Fudim E; Picard O; Peled Y; Eliakim R; Del Tedesco E; Paul S; Roblin X
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1117-1125. PubMed ID: 29446098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes for Standardized Home and Hospital-Based Infusions of Infliximab for Children With Inflammatory Bowel Disease.
    Gupta SR; Bricker J; Boyle BM; Maltz RM; Michel HK; Dotson JL
    J Pediatr Gastroenterol Nutr; 2023 Jun; 76(6):776-781. PubMed ID: 36930973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.
    Cortes X; Borrás-Blasco J; Molés JR; Boscá M; Cortés E
    PLoS One; 2015; 10(5):e0128156. PubMed ID: 26011514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource.
    Kapizioni C; Desoki R; Lam D; Balendran K; Al-Sulais E; Subramanian S; Rimmer JE; De La Revilla Negro J; Pavey H; Pele L; Brooks J; Moran GW; Irving PM; Limdi JK; Lamb CA; ; Parkes M; Raine T
    J Crohns Colitis; 2024 Jun; 18(6):790-800. PubMed ID: 38041850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid infusion of infliximab biosimilars and the incidence and severity of infusion-related reactions in patients with inflammatory bowel disease.
    Rusch C; Wood M; Kennedy AG; Tompkins BJ; Frasca JD
    J Clin Pharm Ther; 2022 Nov; 47(11):1851-1857. PubMed ID: 36134561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Quality Improvement Approach to External Infliximab Infusions in Pediatric Inflammatory Bowel Disease.
    Gupta SR; Crandall WV; Donegan A; Johnson M; Drobnic B; Oates M; Boyle B; Maltz RM; Dotson JL
    J Pediatr Gastroenterol Nutr; 2019 Nov; 69(5):544-550. PubMed ID: 31219936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Home-based Biologic Infusions for Inflammatory Bowel Disease: Are We Ready for Prime Time?
    Tariq R; Loftus EV
    Inflamm Bowel Dis; 2024 Sep; 30(9):1633-1634. PubMed ID: 37819733
    [No Abstract]   [Full Text] [Related]  

  • 32. Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses.
    Harno-Tasihin J; Siregar L; Paajanen M; Arkkila P; Punkkinen J
    Scand J Gastroenterol; 2024 Mar; 59(3):280-287. PubMed ID: 38006219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study.
    Ma C; Evaschesen CJ; Gracias G; Huang VW; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    Can J Gastroenterol Hepatol; 2015; 29(6):309-14. PubMed ID: 26069894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adherence to intravenous biological treatment in inflammatory bowel disease patients during the COVID-19 pandemic.
    Suárez Ferrer C; Pérez Robles T; Martín-Arranz MD
    Rev Esp Enferm Dig; 2021 Feb; 113(2):154. PubMed ID: 33371704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
    Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of Hydrocortisone Premedication Discontinuation in Patients with Inflammatory Bowel Disease on Maintenance Therapy with Infliximab: a Prospective Clinical and Pharmacological Study.
    Tran-Minh ML; Gornet JM; Maillet M; Houze P; Simon M; McLellan P; Hassid D; Vivier-Chicoteau J; Baudry C; Hammoudi N; Allez M
    J Crohns Colitis; 2021 May; 15(5):742-748. PubMed ID: 33205193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A home infliximab infusion program.
    Condino AA; Fidanza S; Hoffenberg EJ
    J Pediatr Gastroenterol Nutr; 2005 Jan; 40(1):67-9. PubMed ID: 15625429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.
    Van Assche G; Vermeire S; Noman M; Amant C; Weyts E; Vleminckx A; Vermeyen MJ; Rutgeerts P
    J Crohns Colitis; 2010 Sep; 4(3):329-33. PubMed ID: 21122522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Tolerability of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease.
    Ma D; Wong W; Aviado J; Rodriguez C; Wu H
    Am J Gastroenterol; 2019 Feb; 114(2):352-354. PubMed ID: 30333541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effect of Biologics on Postoperative Complications in Children With Inflammatory Bowel Disease and Bowel Resection.
    Mitsuya JB; Gonzalez R; Thomas R; El-Baba M
    J Pediatr Gastroenterol Nutr; 2019 Mar; 68(3):334-338. PubMed ID: 30247424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.